Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a Novel TCR-Based T Cell Therapy Company and TIO Bioventures Portfolio Company

Ontario Industry Updates
Written By Viktoriya Shabat

Treadwell Therapeutics today announced the acquisition of TCRyption Inc., a company focusing on novel approaches to TCR based T cell therapy and a TIO Bioventures portfolio company.

The stock swap brings the unique and powerful TCRypt platform technology as well as a large number of TCR candidates with potential anti-cancer utility into Treadwell’s growing and highly productive R&D organization.

Treadwell presented at the 2021 OBIO Investment Summit.

Viktoriya Shabat
Previous

KA Imaging Makes Distribution Deal With PT. Intimedika Puspa Indah in Indonesia
Next

Highmark Interactive Announces Collaboration with Mayo Clinic to Assess Impact of 'Long COVID' on Cognitive Function